title: The role of gp130 receptor cytokines in the regulation of metabolic homeostasis.
abstract: It is well known that obesity is responsible, at least in part, for the increased incidence of chronic diseases such as type 2 diabetes, cardiovascular disease and certain types of cancer. Despite public education programs emphasizing lifestyle modifications to arrest this global pandemic, it is now estimated that 10-15% of the world's population are overweight or obese. As a result, new therapeutic options for the treatment of obesity-related disorders are clearly warranted. Much of the benefit of physical activity has been attributed to several mechanisms including reduced adiposity, increased cardiorespiratory fitness, reduced circulating lipids and the maintenance of muscle mass. However, the observation that the gp130 receptor cytokine interleukin-6 (IL-6) was released from skeletal muscle during exercise to improve metabolic homeostasis altered our understanding of the health benefits of exercise and opened avenues for research into potential novel therapeutics to treat metabolic disease. One gp130 receptor cytokine in particular, ciliary neurotrophic factor (CNTF), a pluripotent neurocytokine, showed efficacy as a potential anti-obesogenic therapy. This review examines the potential of gp130 receptor ligands, with a focus on IL-6 and CNTF as therapeutic strategies to treat obesity-related disorders.
authors.affiliation: Cellular and Molecular Metabolism Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, VIC 3004, Australia Faculty of Biology & Medicine, University of Lausanne, Lausanne,1015 Vaud, Switzerland.
authors.forename: Lena
authors.initials: L
authors.lastname: Cron
authors.affiliation: Cellular and Molecular Metabolism Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, VIC 3004, Australia.
authors.forename: Tamara
authors.initials: T
authors.lastname: Allen
authors.affiliation: Cellular and Molecular Metabolism Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, VIC 3004, Australia Division of Diabetes & Metabolism, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia m.febbraio@garvan.org.au.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Febbraio
mesh_terms: D000818:Animals; D020934:Ciliary Neurotrophic Factor / Q000378:metabolism; D050822:Cytokine Receptor gp130 / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006706:Homeostasis; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008024:Ligands
chemical_list: D020934:Ciliary Neurotrophic Factor; D015850:Interleukin-6; D008024:Ligands; D050822:Cytokine Receptor gp130
keywords: Obesity; Skeletal muscle; Type 2 diabetes